You can buy Deucrava at the lowest price at Nextgen.ooo online pharmacy. Deucravacitinib is a novel, orally available, selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other JAK 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity for this therapeutic target. This selectivity for TYK2 may result in an improved safety profile for deucravacitinib, as non-selective JAK inhibitors are associated with a number of adverse events, such as changes in cholesterol and triglyceride levels and liver and kidney dysfunction.
 
Deucravacitinib was first approved by the FDA in September 2022 for the treatment of moderate to severe plaque psoriasis. It was later approved by Health Canada in November 2022. In clinical studies in patients with psoriasis, deucravacitinib dose-dependently reduced the expression of genes associated with psoriasis, including downregulation of the IL-23 pathway and type I IFN pathway. After 16 weeks of once-daily dosing, deucravacitinib reduced inflammatory markers such as IL-17A, IL-19, and beta-defensin by 47–50%, 72%, and 81–84%, respectively. Deucravacitinib does not affect JAK2-dependent hematopoietic functions.